Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

PAA Research Report May 2020

PAA Research Report - May 2020

Category: Research Notes 2020By PharmAust May 28, 2020

Related posts

JP Equity Partners – Broker Analyst Report – July 2020
June 30, 2020

Recent Articles

May 11, PharmAust Expands Canine Trial to the US
May 11, 2022
May 1, Top 20 Shareholders
May 1, 2022
April 29, Appendix 4C and Quarterly Update
April 29, 2022
April 19, PharmAust Receives $708k R&D Tax Rebate
April 19, 2022

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

PharmAust is a clinical-stage biotech company developing drug discovery IP to treat cancer, viral and neurological diseases. ASX: $PAA FSE: $ECQ

PharmAust @PharmAust·

Trial set to start on potential MND drug

Via @7NewsAustralia
https://7news.com.au/lifestyle/health-wellbeing/trial-set-to-start-on-potential-mnd-drug-c-6932364?utm_campaign=share-icons&utm_source=twitter&utm_medium=social&tid=1653519695767

Reply on Twitter 1529598779078619136 Retweet on Twitter 15295987790786191362 Like on Twitter 15295987790786191362 Twitter 1529598779078619136

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions